Customs Seizures vs Intra-EU Shipping: What Research Buyers Should Know

If you research peptides and buy from more than one source, you have probably noticed that not all shipments feel equally risky. An order that ships from a warehouse in Germany or Poland to an address in France usually just arrives. An order from a US-based vendor, or a Chinese manufacturer selling direct, can sit in limbo for weeks, get a customs notice attached, or simply never show up. That difference is not superstition or bad luck. It is a direct, legally structural consequence of where the shipment starts and which border, if any, it has to cross. This article lays out the legal mechanics behind that difference, what a customs seizure actually is, why research peptides specifically draw scrutiny at external borders, and what "intra-EU shipping" concretely buys a buyer in terms of certainty. It does not offer advice on avoiding declarations, understating values or mislabeling contents. Everything below is a description of how the customs system works and how we operate inside it, not a workaround for it.

The customs border intra-EU shipping never crosses

The European Union operates a customs union among its member states, established under Articles 28 to 30 of the Treaty on the Functioning of the European Union (TFEU). Two things follow from that status. First, customs duties and charges having equivalent effect are prohibited between member states: once goods are inside the union, moving them from a warehouse in one country to a customer in another does not trigger a new duty. Second, the union applies a common external tariff toward goods entering from outside, so the twenty-seven member states act, for customs purposes, as a single territory with one outer edge.

The operational mechanism behind that is the Union Customs Code (Regulation (EU) No 952/2013). When a shipment first enters the EU from outside and clears customs, it is "released for free circulation." From that moment, the goods are treated the same as goods manufactured domestically in the EU: they can move between member states with zero further customs duties, zero customs declarations and zero border checks. This is not a policy that customs officers choose to apply loosely. It is the legal default for any shipment that never leaves the union's territory in the first place.

That is the entire structural argument for intra-EU shipping in one sentence: a parcel that starts in an EU warehouse and ends at an EU address is not crossing a customs border, because there is no customs border between member states to cross. A parcel that starts outside the union, whichever country it comes from, always has to cross one, and everything that follows in this article, declarations, VAT, duty, inspection risk, seizure risk, only applies to that second case.

What a customs seizure actually is, and what happens after

A customs seizure is not the same as a delay. It is a formal legal action: a customs authority takes physical custody of goods it has reasonable cause to believe violate a customs law or an import-enforced regulation, whether because the goods are prohibited outright, misdeclared, undervalued, or missing required paperwork such as an import licence. In most jurisdictions the importer only finds out after the fact, once the parcel has already been detained, not before. From there, the process is often opaque to the recipient: some jurisdictions allow an appeal or a request for release, but a meaningful share of seized, non-compliant parcels are simply destroyed, with no compensation flowing back from the authority to the original shipper.

The financial and practical cost of a seizure lands almost entirely on the buyer and, depending on the jurisdiction, sometimes on the shipper too. Time already spent waiting is lost. Money already paid for goods that never arrive has to be recovered separately from the shipment itself. And a seizure at a given destination is a strong signal that a repeat shipment to the same address, by the same route, is likely to meet the same outcome, which is why vendors who take this seriously generally do not simply try again unchanged.

VAT, duty, and the loophole the EU is actively closing

Two separate charges apply to imports from outside the EU, and buyers frequently conflate them. Import VAT has applied to every commercial import into the EU, regardless of declared value, since the 1 July 2021 e-commerce VAT reform abolished the old EUR 22 VAT-exemption threshold. There has never been a "small enough to skip VAT" allowance since that date. Customs duty is the separate charge, and it retained a EUR 150 duty-exemption threshold even after 2021, meaning a genuinely low-value parcel could still owe VAT but no duty.

That second gap is now closing. Starting 1 July 2026, a flat EUR 3 customs duty applies to every parcel valued under EUR 150 entering the EU from outside. The EUR 150 exemption itself is scheduled to disappear entirely once the EU Customs Data Hub goes live for e-commerce goods on 1 July 2028, after which duty is assessed from the first euro of declared value, with full system rollout across all goods movements targeted for 1 March 2034.

The scale driving this reform is worth stating plainly: roughly 4.6 billion low-value parcels (under EUR 150) entered the EU in 2024, about 12 million a day, up from 1.4 billion in 2022 and 2.3 billion in 2023, with 2025 volume estimated around 5.9 billion, a further 26 percent increase. The European Commission's own figures put 91 percent of those sub-EUR-150 shipments as originating in China, and EU authorities estimate that up to 65 percent of small parcels are undervalued specifically to stay under the old threshold. Undervaluation and misdeclaration are themselves seizure triggers, independent of what the parcel contains, which is part of why customs scrutiny on this category of shipment is rising rather than falling.

None of this touches intra-EU shipping. VAT and duty are import charges, assessed at the point goods enter the union from outside. A parcel that starts inside the union and stays inside it was never an import in the first place, so neither charge applies a second time.

Why research peptides specifically get flagged

Peptides sit in a legally awkward spot at external borders because both EU and US authorities define "medicinal product" by function, not by label. Under Directive 2001/83/EC, the EU's medicinal products code, a substance can be classified and regulated as a medicine if it restores, corrects or modifies a physiological function through a pharmacological, immunological or metabolic action, regardless of whether the packaging says "not for human use" or "research use only." Lawfully importing something that meets that functional definition as a medicine requires a marketing authorisation and an import licence issued by a national medicines authority, something individual researchers and small overseas sellers structurally do not hold.

The enforcement pattern is not hypothetical. Between December 2025 and March 2026, US Customs and Border Protection at Cincinnati intercepted more than 300 mis-manifested master cartons concealing roughly 5,000 individual peptide shipments originating from China, described at the time as the largest single peptide seizure in US history. Named substances in the reporting included retatrutide, alongside several other GLP-1 and metabolic compounds, plus mitochondrial and regenerative peptides. US peptide-related detentions overall rose roughly 40 percent in fiscal year 2025 compared with the prior year. None of this is EU enforcement data, but it is directly relevant to anyone sourcing the same category of substance from the same category of overseas supplier into an EU address: the substances, the concealment tactics and the enforcement direction all track closely across both jurisdictions.

Not all of "Europe" is inside the EU customs union

A common and understandable mistake is treating "shipped from somewhere in Europe" as equivalent to "shipped inside the EU customs union." It is not. Switzerland, Liechtenstein, Norway and Iceland are geographically European and, through EEA or EFTA arrangements, closely integrated with the EU in many respects, but none of them is inside the EU customs union. A medicine-type parcel sent to any of those four still crosses an external customs border and is screened by the destination country's own medicines authority in essentially the same way a shipment from the US or China would be, not the way an intra-EU delivery is handled.

We have applied this distinction directly to our own shipping policy rather than treating it as an abstraction. Switzerland and Liechtenstein are excluded from our shipping map entirely: parcels sent there are screened as medicine-type imports by the destination country's own authority, and Swiss law carries no small-quantity personal-use allowance that would change that outcome. Iceland applies a similar postal restriction on medicine-type imports regardless of origin, so it is closed too. Norway remains open, but on different terms: shipments there proceed at the customer's own import risk rather than under our standard delivery protection. None of this is a judgment on Norwegian, Swiss or Icelandic customers, it is a direct reflection of the fact that all three sit outside the customs union we ship freely within.

The personal-quantity myth

A second common assumption is that a small, clearly personal-use quantity simply will not attract attention. National customs guidance does not support that as a blanket rule even for legitimate medicine imports by individual travellers. German customs (Zoll) guidance, for example, generally permits personal import of medicines only in quantities matching genuine personal need, commonly cited as up to roughly a three-month supply, sourced from a licensed provider, excluding controlled substances, and ideally accompanied by a prescription or a doctor's letter. If a small, clearly personal quantity of an ordinary medicine still needs to satisfy conditions like these to pass cleanly, an unlicensed research peptide shipped commercially from outside the union has no comparable allowance to fall back on. Volume alone does not create a legal pathway that would not otherwise exist.

Peptide stability in transit: why speed is the real argument, not cold-chain

It is tempting to frame EU-warehouse sourcing primarily as a freshness or cold-chain advantage, but that overstates the chemistry. Lyophilized (freeze-dried) peptides are generally stable at room temperature for the several-day window that standard courier transit takes, and do not require refrigerated shipping to survive an ordinary delivery. The practical problem with a customs hold is not that the peptide cannot tolerate a few extra days, it is that a hold extends a multi-day transit into a multi-week, uncontrolled dwell time, in a customs facility not designed or climate-managed for pharmaceutical storage, with no fixed end date and no guarantee of eventual release. The real structural advantage of intra-EU dispatch is legal certainty and predictable transit time, not thermal protection. Reconstituted (mixed with water) peptides are a separate topic entirely, requiring refrigeration regardless of where they were shipped from, and are not affected one way or the other by the customs question discussed here.

How intra-EU dispatch works in practice

We operate from an EU warehouse and ship to EU destinations as intra-community deliveries. Because the goods are already in free circulation inside the union, a shipment from us to a customer in another member state is a domestic-equivalent movement under the customs union rules described above: no customs declaration is filed at a member-state border, because there is no such border in the customs sense to declare anything at. That is a structural property of the route, not a claim about how careful any individual shipment is.

What we add on top of that structural advantage is documentation buyers can actually check rather than take on trust. Every batch we sell carries a third-party certificate of analysis from an independent lab, Janoshik or Liquilabs, published at /coa, and our purity methodology and typical results are explained in detail at /purity. Neither of those pages exists to replace regulatory clearance, they exist so a researcher can verify what a given batch actually contains before deciding whether it fits their work, which matters more, not less, in a category where border authorities are actively tightening enforcement on unverifiable overseas shipments.

Among the peptides most frequently discussed in exactly this customs context, four are worth naming directly because they illustrate different corners of the catalogue: a metabolic compound, a regenerative peptide, a copper-peptide research tool, and the reconstitution water that most liquid protocols depend on.

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

BPC-157regeneration

Gastric pentadecapeptide (15 amino acids) known for exceptional tissue repair properties. Promotes wound healing, angiogenesis, and cytoprotection across tendons, muscles, gut, and nerves. Over 30 years of preclinical research.

GHK-Culongevity

Naturally occurring copper tripeptide complex for skin regeneration and anti-aging research. Stimulates collagen synthesis, accelerates wound healing, and modulates 4000+ genes. Plasma levels decline with age, making it a key target in longevity research.

Bacteriostatic Wateraccessories

USP-grade sterile water with 0.9% benzyl alcohol (near-neutral, ~pH 6) - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.

Accessoriesaccessories

Bacteriostatic water and research supplies

If something still goes wrong

Intra-EU shipping removes the customs-border scenario specifically, it does not remove every possible delivery problem. Parcels can still be lost by a carrier, returned as undeliverable, or misaddressed. We publish exactly what we do in each of those situations, along with the documented exceptions and limits that apply, on our returns page, and that page, not a summary here, is the authoritative source if you need to know what applies to a specific order. We would rather point you to the current, complete policy than restate a partial version of it that could go out of date.

FAQ

This article describes general customs and regulatory mechanics for informational purposes and is not legal advice; all products discussed are sold exclusively as research material for laboratory use, not for human consumption.